Abstract: The invention relates to benzimidazole antibacterial compounds of the Formula I: ##STR1## as described herein, pharmaceutical compositions containing the compounds, and methods for their production and use. These compounds are effective in inhibiting the action of a bacterial histidine protein kinase and are useful as anti-infective agents against a variety of bacterial organisms, including organisms which are resistant to other known antibiotics.

Abstract: A compound of the general formula 1; ##STR1## is disclosed as useful in treating disorders of the central nervous system. Pharmaceutical compositions and methods of treatment are also disclosed.

Abstract: The present invention is directed to an in vitro method of determining the in vivo EPO activity of a sample containing EPO. More particularly, the present method comprises treating a sample containing EPO under conditions which remove desialylated EPO, and measuring the in vitro EPO activity of the resulting treated sample. In a preferred embodiment, desialylated EPO is removed from the sample by incubating the sample with cells of the human hepatoma cell line HepG2, and in vitro EPO activity is determined by incubating the treated sample with cells of an EPO-responsive cell line and measuring the proliferation or viability of the EPO-responsive cells. The present invention is useful, for example, in quantitating the biologically active EPO in a variety of sample types.

Abstract: Compounds of Formula I ##STR1## and Formula III ##STR2## which are useful in the treatment of thrombin and trypsin related disorders.

Abstract: The binding specificity of the murine OKT3 has been transferred into a human antibody framework in order to reduce its immunogenicity. This "humanized" anti-CD3 mAb (gOKT3-5) was previously shown to retain, in vitro, all the properties of native OKT3, including T cell activation which has been correlated, in vivo, with the severe side-effects observed in transplant recipients after the first administration of the mAb. Disclosed is a single amino acid mutation from a leucine to a glutamic acid at position 235 in the Fc receptor (FcR) binding segment of the gOKT3-5 mAb to produce Glu-235 mAb. Also disclosed is an amino acid mutation from the contiguous phenylalanine at position 234 to a leucine (Leu-234).

Abstract: Compounds of Formula I ##STR1## useful in the treatment of inflammatory disorders.

Abstract: A punch assembly for punching samples of dried blood spots (DBSs) from paper card samples includes: a base member, a cartridge and at least one cutting pin. The base member includes a bottom platform having an upper surface defining a track therein, an upper platform, at least one support post disposed between and spacing the bottom platform and the upper platform, a biasing element for biasing the upper platform in a direction away from the bottom platform, and a mechanism associated with the base member for moving the upper platform toward the bottom platform. The upper platform is slidably connected to the at least one support post such that the upper platform is movable therealong with respect to the bottom platform. The cartridge functions to hold an object to be punched and at least one cutting pin. The cartridge defines at least one hole therethrough for receiving the cutting pin. In addition, the cartridge is sized to be received in the track defined in the bottom platform.

Abstract: The invention relates to benzoxazine and pyrido-oxazine antibacterial compounds of the general formula: ##STR1## wherein the moiety Q is a fused phenyl or fused pyridyl moiety as herein described, pharmaceutical compositions containing the compounds, methods for their production and their use in treating bacterial infections.

Abstract: Compounds of Formula I ##STR1## useful in the treatment of inflammatory disorders.

Abstract: Generally, this invention relates to dosage containers. More specifically this invention relates to dosage containers which help identify a daily regimen of dosages, or a particular time period of dosages in a day. Most specifically, this invention relates to a dosage container which provides dosages in a linear fashion in a one-to-one relationship for the date or timing of dosages, where such dosages are contained on a card, with a blister package holding the dosages.

Abstract: Tetracyclic compounds having the following structure are described: ##STR1## wherein R.sub.1 -R.sub.10 are as defined. The tetracyclic compounds are capable of potent effects on steroid sensitive tissues and have demonstrated increased uterine weight, antiovulatory effects and potent steroid receptor binding. The compounds have therapeutic utility in reproductive applications such as fertility control, labor induction, ovulation induction and spermatogenesis. Methods for preparing the tetracyclic compounds from substituted indanones are also described.

Abstract: Compounds of the Formula I: ##STR1## useful in the treatment of thrombin and trypsin related disorders.

Abstract: Compounds of the Formula I: ##STR1## useful in the treatment of thrombin and trypsin related disorders.

Abstract: A compound of the general formula 1; ##STR1## is disclosed as useful in treating disorders of the central nervous system. Pharmaceutical compositions and methods of treatment are also disclosed.

Abstract: This invention relates to a substantially circular tablet dispenser component system which may be adapted for a variable day start of a prescribed periodic tablet regimen. Also provided are a tablet dispenser kit, a tablet packge adapted for filling the tablet dispenser system, methods of filling the tablet dispenser of the invention and methods of administering a prescribed regimen of medication using the tablet dispenser system of the invention.

Abstract: The invention relates to a method of detecting a site of infection or inflammation, and a method for treating such infection or inflammation, in an individual by administering to the individual a diagnostically or therapeutically effective amount of detectably labeled, therapeutic, or therapeutically-conjugated, chemotactic peptide that accumulates substantially at the infected or inflamed site, said chemotactic peptide having the general structureX--Y--Leu--Phe--?Z!.sub.n --Wwherein:X is an amino protecting group,Y is an amino acid residue,Z is a spacer sequence,n is 0 or 1, andW is a labeling or attachment substituent.

Abstract: 2,5-Disubstituted thiophene derivatives, and more particularly, to 2-aryloxy-5-alkansulfonamido-thiophenes of the general formula: ##STR1## Wherein, R.sub.2 is CF.sub.3, C.sub.1 -C.sub.10 alkyl, or phenyl;X is O, S, or CH.sub.2 ; andR is aryl, C.sub.1 -C.sub.10 alkyl, or C.sub.3 -C.sub.8 cycloalkyl; which compounds are pharmacologically active in alleviating inflammation, asthma, arthritis, hypersensitivity, myocardial ischemia and dermatological conditions, such as, psoriasis and dermatitis, and gastrointestinal inflammatory conditions, such as, inflammatory bowel syndrome.

Abstract: The invention relates to diaryl antimicrobial compounds of the general formula: ##STR1## where G, E L, J, q, m, X, Ar, W, p, n and A are as described herein, pharmaceutical compositions containing the compounds, methods for their production and their use in treating bacterial infections.

Abstract: Nipecotic acid-derived compounds of formula (I): ##STR1## are disclosed as useful in treating platelet-mediated thrombotic disorders.

Abstract: Anticonvulsant derivatives useful in treating neuropathic pain are disclosed.